Beyond Politics: The Upside of China as an Investment partner

By DeeDee DeMan – In the swirl of geopolitical strife, the wisdom of China’s “midlife,” at 4000 years old, is reflecting in their long term view of investing in US-driven Biotech. Their acceptance of a very different definition of, “short term,” than we use here in the US, is breathing LYFE into companies that are not the “usual suspects.” Innovation backed by thousands of years- of wisdom.

Less than two years after its launch, Shanghai-based LYFE Capital has come up with an upsized biotech venture fund. And this time it’s spreading its wings directly into the US market, where it plans to start making some new bets on a slate of life science ventures interested in developing a China strategy.